The Gut–Brain Axis: Part Three: Short-Chain Fatty Acids and the Concentration Gradient

Abstract

Short-chain fatty acids are the strongest part of the gut–brain story: named molecules, named receptors, a documented epigenetic mechanism, and — unusually for this field — a small number of controlled human experiments.

This part follows the 2022 review by Kenneth O'Riordan, John Cryan and colleagues at APC Microbiome Ireland, and it tracks a single quantity: how much of these compounds is where.

The concentration gradient from colon to bloodstream turns out to be the most informative number in the whole series, and it explains why the human interventions that work are the ones delivered to the gut rather than swallowed.

1.What They Are and Where They Come From

Short-chain fatty acids are saturated fatty acids of one to six carbon atoms, produced by bacterial fermentation of dietary fibre. Three dominate: acetate with two carbons, propionate with three, butyrate with four.

They are not supplements in the ordinary sense. They are what happens to fibre that a human cannot digest, in the presence of bacteria that can.

The review names the producing genera for anyone designing an intervention — Akkermansia, Bifidobacterium, Lactobacillus, Ruminococcus, Blautia, Bacteroides, Roseburia, Prevotella, Faecalibacterium and others — which is the level of specificity the field has reached on the input side.

2.The Gradient

Here are the numbers the review tabulates, and they should be read in sequence.

In the gut, acetate is present in wet faeces at around 100 millimolar.

In peripheral circulation, mean concentrations are roughly 70 micromolar for acetate, 5 micromolar for propionate and 4 micromolar for butyrate.

In cerebrospinal fluid, acetate has been measured at 58 to 69 micromolar across two independent reports — comparable to blood.

Read that as a sequence and the shape of the problem appears. Between the colon and the bloodstream, acetate falls by roughly three orders of magnitude. Butyrate — the molecule carrying most of the mechanistic story, as a histone deacetylase inhibitor — circulates at single-digit micromolar.

Whatever these compounds do systemically, they do it at concentrations vastly lower than those in the compartment where they are made. The gut is not a delivery system to the blood; it is where most of the signal stays.

3.How They Move, and Where They Act First

Transport across epithelium uses the sodium-coupled monocarboxylate transporter SMCT1 and the pH-dependent hydrogen-coupled transporters MCT1 and MCT4. Other transporters exist and are considered quantitatively less important.

The review makes a point that reframes the whole question: short-chain fatty acids can exert effects on the gut before they are taken into the general circulation, through G-protein-coupled receptors and hydroxycarboxylic acid receptor 2, mediating an anti-inflammatory effect.

That is the mechanistic resolution of the gradient. The low blood concentrations are not a failure of the system. Much of the action is local — on enteric neurons, immune cells and the epithelium — with the systemic and vagal consequences following from events that happened in the intestine.

Diet and transit time modulate the process. A diet high in resistant starch increased expression of the MCT1 transporter in pigs, and faster colonic transit in a model system increased faecal short-chain fatty acid content — probably because absorption was impeded, which the authors flag as important when interpreting faecal measurements.

4.The Human Experiments

Two controlled human studies in this review are worth more than the rest of the literature combined, because both delivered the compound to the colon rather than relying on oral supplementation.

In the first, colon-delivered short-chain fatty acids attenuated the cortisol response to psychosocial stress in men. That is a physiological stress endpoint, measured, in humans, following a targeted delivery.

In the second, a randomised crossover study in healthy adults delivered propionate to the colon as an inulin-propionate ester. It found no differences in blood glucose or insulin concentrations, and no changes in neuropeptide levels. But functional imaging indicated that the ester reduced anticipatory reward responses in the human striatum to high-energy foods.

Both results are real and both are narrow. A cortisol response in men, and a striatal reward signal to pictures of food. Neither is a claim about mood, memory or cognition, and neither followed from swallowing a capsule of anything.

The design detail is the finding. When this field takes care to get the compound where it acts, it produces measurable human effects — in specific systems, at specific moments.

5.What the Authors Are Careful About

The review's framing of its own subject is explicitly forward-looking: ongoing research is focused on the entry of short-chain fatty acids into systemic circulation from the gut lumen, their migration to cerebral circulation and across the blood–brain barrier, and their potential to exert acute and chronic effects on brain structure and function.

Potential. Ongoing. That is the status of brain-level effects in the most authoritative treatment of the best-characterised messenger class in this field.

They also note that establishing guidelines for safe levels of short-chain fatty acid administration in humans remains outstanding — a reminder that these are physiologically active compounds rather than nutrients with a known safe range.

Editorial Comment

MindHeaven® makes no claim relating to the microbiome, short-chain fatty acids, or any microbial metabolite, and none of our formulations is designed to act on them.

Across three parts, the gut–brain axis is real, physically instantiated and better specified than most of nutritional science. What has not been established is that manipulating the microbiome in a healthy adult reliably changes how they think or feel. The useful stance is to treat the mechanism as established and the applications as open — and to notice which of the two any given product is borrowing from.

One point is worth carrying away because it costs nothing and is well supported. The messengers in this story are produced by fermenting dietary fibre. Whatever remains uncertain about probiotic capsules, the substrate that the best-characterised part of this system runs on is fibre, and most people do not eat enough of it.

That is not a claim about our products. We do not sell fibre.